FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients should be advised that dolutegravir, lamivudine or any other antiretroviral therapy does not cure HIV infection and that they may still develop opportunistic infections and other complications of HIV infection.
Croatian: Bolesnike treba upozoriti da liječenje dolutegravirom, lamivudinom ili bilo kojim drugim antiretrovirusnim lijekom ne može izliječiti HIV infekciju, zbog čega se i dalje mogu javljati oportunističke infekcije i druge komplikacije povezane s HIV infekcijom.
English: In long-term oral carcinogenicity studies in rats and mice, lamivudine did not show any carcinogenic potential.
Croatian: U dugoročnim ispitivanjima kancerogenosti peroralnih doza u štakora i miševa lamivudin nije pokazao kancerogeni potencijal.
English: Stopping Dovato can affect your health and how future treatment works.
Croatian: Prekid primjene lijeka Dovato može utjecati na Vaše zdravstveno stanje i na učinak budućeg liječenja.
English: It is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Croatian: Preporučuje se da žene s HIV infekcijom ni pod kojim uvjetom ne doje svoju dojenčad, kako bi se izbjegao prijenos HIV-a.
English: In vitro lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of cladribine loss of efficacy in case of combination in the clinical setting.
Croatian: In vitro lamivudin inhibira unutarstaničnu fosforilaciju kladribina, što može dovesti do rizika od gubitka djelotvornosti kladribina u slučaju kombinirane primjene u kliničkim uvjetima.
English: Ledipasvir/Sofosbuvir/ Lamvudine (with abacavir)
Croatian: ledipasvir / sofosbuvir / lamivudin (s abakavirom)
English: Lamivudine ↔ Ledipasvir ↔ Sofosbuvir ↔
Croatian: lamivudin ↔ ledipasvir ↔ sofosbuvir ↔
English: The most severe adverse reaction reported with dolutegravir was a hypersensitivity reaction that included rash and severe liver effects (see section 4.4).
Croatian: Najteža nuspojava prijavljena kod primjene dolutergravira bila je reakcija preosjetljivosti koja je uključivala osip i teške učinke na jetru (vidjeti dio 4.4).
English: Lamivudine triphosphate shows significantly less affinity for host cell DNA polymerases.
Croatian: Lamivudintrifosfat pokazuje značajno manji afinitet za DNK polimeraze stanica domaćina.
English: Animal studies showed lamivudine may inhibit cellular DNA replication (see section 5.3).
Croatian: Ispitivanja na životinjama pokazala su da lamivudin može inhibirati replikaciju stanične DNK (vidjeti dio 5.3).
English: Some late-onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour).
Croatian: Rijetko su prijavljeni neurološki poremećaji s kasnim nastupom (hipertonija, konvulzije, neuobičajeno ponašanje).
English: Don't stop unless your doctor tells you to.
Croatian: Nemojte ga prestati uzimati, osim ako Vam to ne savjetuje liječnik.
English: Your doctor may decide to adjust your dose or that you need extra check ups.
Croatian: Liječnik će možda odlučiti prilagoditi dozu lijeka ili dogovoriti dodatne kontrolne preglede.
English: The incidence of neural tube defects in the general population ranges from 0.5-1 case per 1,000 live births (0.05-0.1%).
Croatian: Incidencija oštećenja neuralne cijevi u općoj populaciji kreće se u rasponu od 0,5 do 1 slučaja na 1000 živorođene djece (0,05 - 0,1%).
English: Cimetidine
Croatian: cimetidin
English: Dolutegravir has not been studied in patients on dialysis, though differences in exposure are not expected.
Croatian: Dolutegravir se nije ispitivao u bolesnika na dijalizi, ali se ne očekuju razlike u izloženosti.
English: Although lamivudine is a substrate of BCRP and P-gp in vitro, given its high absolute bioavailability, (see section 5.2), inhibitors of these efflux transporters are unlikely to result in a clinically relevant impact on lamivudine concentrations.
Croatian: Iako je lamivudin supstrat za BCRP i P-gp in vitro, s obzirom na njegovu veliku apsolutnu bioraspoloživost (vidjeti dio 5.2), nije vjerojatno da će inhibitori tih efluksnih prijenosnika imati klinički značajnog utjecaja na koncentracije lamivudina.
English: These changes are not clinically significant.
Croatian: Navedene promjene nisu klinički značajne.
English: • wind (flatulence)
Croatian: • vjetrovi (flatulencija)
English: Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.
Croatian: Bolesnike treba uputiti da potraže liječničku pomoć ako osjete bolove i probadanja u zglobovima, ukočenost zglobova ili teškoće pri kretnjama.
English: The absolute bioavailability of dolutegravir has not been established.
Croatian: Apsolutna bioraspoloživost dolutegravira nije ustanovljena.
English: Dovato is used to treat HIV in adults and adolescents over 12 years old who weigh at least 40 kg.
Croatian: Dovato se koristi za liječenje HIV infekcije u odraslih i adolescenata starijih od 12 godina i tjelesne težine od najmanje 40 kg.
English: Some people taking combination therapy for HIV develop a condition called osteonecrosis.
Croatian: U nekih osoba koje uzimaju kombiniranu terapiju za HIV infekciju može se razviti bolest koja se zove osteonekroza.
English: Dovato contains dolutegravir and lamivudine, therefore any interactions identified for these individually are relevant to Dovato.
Croatian: Dovato sadrži dolutegravir i lamivudin, pa su sve interakcije utvrđene kod njihove pojedinačne primjene relevantne i za Dovato.
English: As neural tube defects occur within the first 4 weeks of foetal development (at which time the neural tubes are sealed) this potential risk would concern women exposed to dolutegravir at the time of conception and in early pregnancy.
Croatian: Budući da se oštećenja neuralne cijevi javljaju unutar prva 4 tjedna razvoja ploda (kada dolazi do zatvaranja neuralne cijevi), taj se mogući rizik odnosi na žene koje su dolutegraviru izložene u vrijeme začeća i u ranoj fazi trudnoće.
English: • cladribine, to treat leukaemia or multiple sclerosis
Croatian: • kladribin, koji se koristi za liječenje leukemije ili multiple skleroze
English: Dolutegravir has a terminal half-life of ~14 hours.
Croatian: Dolutegravir ima terminalni poluvijek od ~ 14 sati.
English: Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine (see section 5.1).
Croatian: Dovato je indiciran za liječenje infekcije virusom humane imunodeficijencije tipa 1 (HIV-1) u odraslih i adolescenata starijih od 12 godina i tjelesne težine od najmanje 40 kg koji nemaju potvrđenu ni suspektnu rezistenciju na skupinu inhibitora integraze ili lamivudin (vidjeti dio 5.1).
English: Dolutegravir is primarily metabolized and eliminated by the liver.
Croatian: Dolutegravir se prvenstveno metabolizira i izlučuje kroz jetru.
English: Pharmacokinetic data for dolutegravir and lamivudine in subjects >65 years of age are limited.
Croatian: Farmakokinetički podaci za dolutegravir i lamivudin u ispitanika starijih od 65 godina su ograničeni.
English: amylase elevations
Croatian: povišene vrijednosti amilaze
English: Therefore, patients should remain under close clinical observation by physicians experienced in the treatment of these associated HIV diseases.
Croatian: Stoga bolesnici moraju biti pod strogim kliničkim nadzorom liječnika s iskustvom u liječenju tih bolesti povezanih s
English: In vivo, dolutegravir may increase plasma concentrations of medicinal products in which excretion is dependent upon OCT2 or MATE-1 (e.g. metformin) (see Table 1 and section 4.3).
Croatian: In vivo dolutegravir može povećati plazmatske koncentracije lijekova čije izlučivanje ovisi o OCT2 ili MATE-1 (npr. metformin) (vidjeti Tablicu 1 i dio 4.3).
English: In vitro, lamivudine was an inhibitor of OCT1 and OCT2; the clinical consequences are not known.
Croatian: In vitro je lamivudin inhibirao OCT1 i OCT2, no kliničke posljedice tog učinka nisu poznate.
English: Dolutegravir may increase plasma concentrations of medicinal products in which excretion is dependent upon OAT3.
Croatian: Dolutegravir može povećati plazmatske koncentracije lijekova čije izlučivanje ovisi o OAT3.
English: These include:
Croatian: Ona uključuju:
English: In 100% human serum, the mean fold shift for dolutegravir activity was 75 fold, resulting in protein adjusted IC90 of 0.064 µg/mL.
Croatian: U 100%-tnom ljudskom serumu srednja vrijednost promjene aktivnosti dolutegravira iznosila je 75 puta, što je za posljedicu imalo vrijednost IC90 prilagođenu za proteine od 0,064 µg/ml.
English: The results from two in vivo rat micronucleus tests with lamivudine were negative.
Croatian: Rezultati dva in vivo mikronukleusnog testa lamivudina na štakorima bili su negativni.
English: Other medicines and Dovato Tell your doctor if you are taking, have recently taken or might take any other medicines.
Croatian: Obavijestite svog liječnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
English: It is unknown if all or part of this is due to unabsorbed active substance or biliary excretion of the glucuronidate conjugate, which can be further degraded to form the parent compound in the gut lumen.
Croatian: Nije poznato je li sve ili samo dio toga posljedica neapsorpcije djelatne tvari ili izlučivanja glukuronidacijskog konjugata u žuč, koji se u lumenu crijeva može dalje razgraditi i činiti ishodišni spoj.
English: The efficacy of Dovato is supported by data from 2 identical 148-week, Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority controlled trials GEMINI-1 (204861) and GEMINI-2 (205543).
Croatian: Djelotvornost lijeka Dovato podupiru podaci iz 2 identična, 148-tjedna, randomizirana, dvostruko slijepa, multicentrična, kontrolirana ispitivanja neinferiornosti faze III s paralelnim skupinama pod nazivom GEMINI-1 (204861) i GEMINI-2 (205543).
English: Dolutegravir was not carcinogenic in long term studies in the mouse and rat.
Croatian: Dolutegravir nije bio kancerogen u dugotrajnim ispitivanjima na miševima i štakorima.
English: The frequency of this is unknown (see section 4.4).
Croatian: Učestalost tih događaja nije poznata (vidjeti dio 4.4).
English: Dovato film-coated tablets are oval, biconvex, white tablets debossed with 'SV 137' on one face.
Croatian: Dovato filmom obložene tablete su ovalne, bikonveksne, bijele tablete s utisnutom oznakom „SV 137” na jednoj strani.
English: Interaction studies have only been performed in adults.
Croatian: Pedijatrijska populacija Ispitivanja interakcija provedena su samo u odraslih.
English: Dolutegravir increased metformin concentrations.
Croatian: Dolutegravir je povećao koncentracije metformina.
English: • lack of energy (fatigue)
Croatian: • nedostatak energije (umor)
English: The higher lamivudine Cmax, is not considered clinically relevant.
Croatian: Veći Cmax lamivudina ne smatra se klinički značajnim.
English: No dosage adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh grade A or B).
Croatian: Nije potrebno prilagođavati dozu u bolesnika s blagim ili umjerenim oštećenjem jetrene funkcije (Child-Pugh stadij A ili B).
English: The recommended dose of Dovato in adults and adolescents is one 50 mg/300 mg tablet once daily.
Croatian: Preporučena doza lijeka Dovato u odraslih i adolescenata je jedna tableta od 50 mg/300 mg jedanput na dan.
English: Dovato is indicated in the absence of documented or suspected resistance to the integrase inhibitor class and to lamivudine (see section 4.1).
Croatian: Dovato je indiciran u slučajevima kada ne postoji dokumentirana ni suspektna rezistencija na razred inhibitora integraze i lamivudin (vidjeti dio 4.1).
English: Lamivudine has not shown any genotoxic activity in the in vivo studies.
Croatian: Lamivudin nije pokazao genotoksično djelovanje u ispitivanjima in vivo.
English: No clinically significant drug interactions are expected between dolutegravir and lamivudine.
Croatian: Ne očekuju se klinički značajne interakcije između dolutegravira i lamivudina.
English: Dolutegravir and lamivudine have been shown to inhibit replication of lab-strains and clinical isolates of HIV in a number of cell types, including transformed T cell lines, monocyte/macrophage derived lines and primary cultures of activated peripheral blood mononuclear cells (PMBCs) and monocyte/macrophages.
Croatian: Pokazalo se da dolutegravir i lamivudin inhibiraju replikaciju laboratorijskih sojeva i kliničkih izolata HIV-a u nizu različitih vrsta stanica, uključujući transformirane stanične linije T-limfocita, stanične linije nastale od monocita/makrofaga te primarne kulture aktiviranih mononuklearnih stanica periferne krvi i monocita/makrofaga.
English: The frequency category of rare was estimated based on post-marketing reports.
Croatian: Kategorija učestalosti „rijetko” procijenjena je na temelju prijava nakon stavljanja lijeka u promet.
English: Oval, biconvex, white, film coated tablet, approximately 18.5 x 9.5 mm, debossed with “SV 137” on one face.
Croatian: Ovalna, bikonveksna, bijela, filmom obložena tableta dimenzija približno 18,5 x 9,5 mm, s utisnutom oznakom „SV 137” na jednoj strani.
English: Delay in stopping treatment with Dovato or other suspect active substances after the onset of hypersensitivity may result in a life-threatening allergic reaction.
Croatian: Odgađanje prekida liječenja lijekom Dovato ili drugim suspektnim djelatnim tvarima nakon pojave preosjetljivosti može uzrokovati po život opasnu alergijsku reakciju.
English: Increases in serum creatinine occurred within the first four weeks of treatment with dolutegravir plus lamivudine and remained stable through 48 weeks.
Croatian: Povećanja koncentracije kreatinina u serumu nastupila su unutar prva četiri tjedna liječenja dolutegravirom u kombinaciji s lamivudinom, nakon čega su vrijednosti bile stabilne do 48. tjedna.
English: • suicidal thoughts (particularly in patients who have had depression or mental health problems before).
Croatian: • suicidalne misli (osobito u bolesnika koji su ranije imali problema s depresijom ili mentalnim zdravljem)
English: Dolutegravir is the predominant circulating compound in plasma; renal elimination of unchanged active substance is low (< 1% of the dose).
Croatian: Dolutegravir je glavni cirkulirajući spoj u plazmi; eliminacija djelatne tvari u nepromijenjenu obliku kroz bubrege je niska (< 1% doze).
English: Based on in vivo and/or in vitro data, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of any major enzyme or transporter such as CYP3A4, CYP2C9 and P-gp (for more information see section 5.2).
Croatian: Na temelju in vivo i/ili in vitro podataka, ne očekuje se da će dolutegravir utjecati na farmakokinetiku lijekova koji su supstrati bilo kojeg od glavnih enzima ili prijenosnika, kao što su CYP3A4, CYP2C9 i P-gp (za više informacija vidjeti dio 5.2).
English: There is no specific treatment for an overdose of Dovato.
Croatian: Nema specifičnog liječenja za predoziranje lijekom Dovato.
English: dizziness, somnolence
Croatian: omaglica, somnolencija
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING INTERMEDIATE CARTON (WITHOUT BLUE BOX - COMPONENT OF MULTIPACK)
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU SREDNJE PAKIRANJE (BEZ PLAVOG OKVIRA - SASTAVNI DIO VIŠESTRUKOG PAKIRANJA)
English: Keep this medicine out of the sight and reach of children.
Croatian: Kako čuvati Dovato Lijek čuvajte izvan pogleda i dohvata djece.
English: • suicidal attempt (particularly in patients who have had depression or mental health problems before)
Croatian: • pokušaj samoubojstva (osobito u bolesnika koji su ranije imali problema s depresijom ili mentalnim zdravljem)
English: 4.3 Contraindications Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Croatian: Preosjetljivost na djelatne tvari ili neku od pomoćnih tvari navedenih u dijelu 6.1.
English: Medicinal products that induce those enzymes or transporters may decrease dolutegravir plasma concentration and reduce the therapeutic effect of dolutegravir.
Croatian: Lijekovi koji induciraju navedene enzime ili prijenosnike mogu smanjiti koncentraciju dolutegravira u plazmi i tako oslabiti njegov terapijski učinak.
English: • palpitations (rapid or irregular heartbeat) or tremor
Croatian: • osjećaj lupanja srca (brzi ili nepravilni otkucaji srca) ili nevoljno drhtanje
English: Dolutegravir is primarily metabolized via UGT1A1 with a minor CYP3A component (9.7% of total dose administered in a human mass balance study).
Croatian: Dolutegravir se prvenstveno metabolizira posredstvom UGT1A1, a manjim dijelom posredstvom CYP3A (9,7% ukupne doze primijenjene u ispitivanju masene bilance u ljudi).
English: The carcinogenic potential of a combination of dolutegravir and lamivudine has not been tested.
Croatian: Kancerogeni potencijal kombinacije dolutegravira i lamivudina nije se ispitivao.
English: More than 1000 outcomes from second and third trimester exposure to dolutegravir in pregnant women indicate no evidence of increased risk of malformative and foeto/neonatal negative effects.
Croatian: Podaci o više od 1000 ishoda trudnoća nakon izloženosti trudnica dolutegraviru u drugom i trećem tromjesečju ne ukazuju ni na kakve dokaze o povećanom riziku od malformacija i negativnih učinaka na plod/novorođenče.
English: These findings should be considered for any child exposed in utero to nucleoside and nucleotide analogues, who presents with severe clinical findings of unknown aetiology, particularly neurologic findings.
Croatian: Navedene nalaze treba uzeti u obzir kod svakog djeteta koje je bilo izloženo nukleozidnim i nukleotidnim analozima in utero, a koje ima tešku kliničku sliku nepoznate etiologije, osobito ako se radi o neurološkim stanjima.
English: Although the aetiology is considered to be multifactorial (including corticosteroid use, biphosphonates, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported in patients with advanced HIV-disease and/or long-term exposure to CART.
Croatian: Iako se smatra da je etiologija višeuzročna (uključujući primjenu kortikosteroida, bifosfonate, konzumiranje alkohola, jaku imunosupresiju, viši indeks tjelesne mase), slučajevi osteonekroze prijavljeni su u bolesnika s uznapredovalom HIV bolešću i/ili bolesnika dugotrajno izloženih kombiniranoj antiretrovirusnoj terapiji.
English: In previously untreated patients receiving dolutegravir + 2 NRTIs in Phase IIb and Phase III, no development of resistance to the integrase inhibitor class, or to the NRTI class was seen (n=1118 follow-up of 48-96 weeks).
Croatian: U prethodno neliječenih bolesnika koji su u ispitivanjima faze IIb i faze III primali dolutegravir + 2 NRTI-ja nije primijećen razvoj rezistencije na skupinu inhibitora integraze ni na skupinu NRTI-ja (n=1118; praćenje u trajanju od 48 - 96 tjedana).
English: • difficulty breathing.
Croatian: • otežano disanje
English: The unbound fraction of dolutegravir in plasma is increased at low levels of serum albumin (<35 g/L) as seen in subjects with moderate hepatic impairment.
Croatian: Udio nevezanog dolutegravira u plazmi povećava se pri niskim razinama albumina u serumu (< 35 g/l), što je primijećeno u ispitanika s umjerenim oštećenjem jetrene funkcije.
English: Typically, such reactions have been observed within the first few weeks or months of initiation of CART.
Croatian: Takve su se reakcije obično javljale unutar prvih nekoliko tjedana ili mjeseci nakon uvođenja kombinirane antiretrovirusne terapije.
English: Polymorphisms in drug metabolising enzymes
Croatian: Polimorfizmi enzima koji metaboliziraju lijekove
English: There are no clinical study data on the effects of Dovato in the paediatric population.
Croatian: Nema podataka iz kliničkih ispitivanja o učincima lijeka Dovato u pedijatrijskoj populaciji.
English: No dose adjustment is necessary (see section 5.2).
Croatian: Nije potrebno prilagođavati dozu (vidjeti dio 5.2).
English: The efficacy of Dovato, or the dual combination of dolutegravir plus lamivudine (as single entities) has not been studied in children or adolescents.
Croatian: Djelotvornost lijeka Dovato ili dvojne kombinacije dolutegravira i lamivudina (kao zasebnih lijekova) nije se ispitivala u djece i adolescenata.
English: Lamivudine, via its active metabolite 5'-triphosphates (TP) (an analogue for cytidine), inhibits reverse transcriptase of HIV-1 and HIV-2 through incorporation of the monophosphate form into the viral DNA chain, resulting in chain termination.
Croatian: Lamivudin putem svojih aktivnih 5'-trifosfatnih metabolita (analoga citidina) inhibira reverznu transkriptazu HIV-1 i HIV-2 ubacivanjem monofosfatnog oblika u lanac virusne DNK, što dovodi do prekida tog lanca.
English: Effect of dolutegravir and lamivudine on the pharmacokinetics of other medicinal products
Croatian: Učinak dolutegravira i lamivudina na farmakokinetiku drugih lijekova
English: The table should not be considered exhaustive but is representative of the classes studied.
Croatian: Tablica ne uključuje sve moguće interakcije, ali je reprezentativna za ispitivane skupine lijekova.
English: Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to CART.
Croatian: Prijavljeni su slučajevi osteonekroze, osobito u bolesnika s općepoznatim faktorima rizika, uznapredovalom HIV bolešću ili dugotrajnom izloženošću kombiniranoj antiretrovirusnoj terapiji.
English: There is no evidence that common polymorphisms in drug metabolising enzymes alter dolutegravir pharmacokinetics to a clinically meaningful extent.
Croatian: Nema dokaza da česti polimorfizmi enzima koji metaboliziraju lijekove mijenjaju farmakokinetiku dolutegravira u klinički značajnoj mjeri.
English: If the patient misses a dose of Dovato, the patient should take Dovato as soon as possible, providing the next dose is not due within 4 hours.
Croatian: Ako bolesnik propusti dozu lijeka Dovato, treba je uzeti što je prije moguće, pod uvjetom da je do sljedeće doze preostalo najmanje 4 sata.
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE LABEL
Croatian: PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKIRANJU NALJEPNICA BOCE
English: In these cases the physician should refer to the individual product information for dolutegravir.
Croatian: U tim slučajevima liječnik treba pročitati informacije o lijeku za tu formulaciju dolutegravira.
English: Dolutegravir had no pharmacodynamic effect on Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and progesterone.
Croatian: Dolutegravir nije utjecao na farmakodinamiku luteinizirajućeg hormona (LH), folikulostimulirajućeg hormona (FSH) ni progesterona.
English: Patients should be informed that dizziness and somnolence has been reported during treatment with dolutegravir.
Croatian: Bolesnike treba upozoriti da su tijekom liječenja dolutegravirom prijavljene omaglica i somnolencija.
English: Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Croatian: Prijavljeni su i autoimuni poremećaji (poput Gravesove bolesti i autoimunog hepatitisa); međutim, prijavljeno vrijeme do pojave je različito, pa se ti događaji mogu javiti i mjesecima nakon uvođenja liječenja (vidjeti dio 4.4).
English: In lactating rats that received a single oral dose of 50 mg/kg at 10 days postpartum, dolutegravir was detected in milk at concentrations typically higher than blood.
Croatian: U ženki štakora u laktaciji koje su primile jednu peroralnu dozu od 50 mg/kg 10 dana nakon okota, dolutegravir je pronađen u mlijeku u koncentracijama koje su obično bile veće od onih u krvi.
English: Clinically significant interaction unlikely.
Croatian: Nije vjerojatno da će doći do klinički značajne interakcije.